Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews
Abstract Background Relenza represents the first neuraminidase inhibitor (NI), a class of drugs that also includes the drug Tamiflu. Although heralded as breakthrough treatments in influenza, NI efficacy has remained highly controversial. A key unsettled question is why the United States Food and Dr...
Main Authors: | Shai Mulinari, Courtney Davis |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-11-01
|
Series: | Health Research Policy and Systems |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12961-017-0259-8 |
Similar Items
-
Plasticity of the 340-loop in influenza neuraminidase offers new insight for antiviral drug development
by: Han, Nanyu, et al.
Published: (2021) -
A Novel Series of Sialic Acid-Based Influenza Virus Inhibitors that Target Influenza Virus Neuraminidase
by: Mark von Itzstein
Published: (2019-08-01) -
Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine
by: Luca T. Giurgea, et al.
Published: (2020-07-01) -
The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination
by: Madhusudan Rajendran, et al.
Published: (2021-08-01) -
H3N2 Influenza Virus Pathogenesis, Transmission and Complications: A Narrative Review
by: Vaishnavi Uttam Goradwar, et al.
Published: (2024-03-01)